NeuroVive receives research grant from Vinnova for development of the NVP015 genetic mitochondrial disease project
Lund, Sweden, 1 June 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the company receives close to 1 million SEK in a research grant from Swedish innovation agency, Vinnova, for developing a new treatment for genetic mitochondrial diseases.NeuroVive receives the grant from Vinnova’s 2017 Swelife call to continue progressing the preclinical project NVP015. The cutting edge NVP015 project is aimed at developing a new pharmacological treatment for patients with Complex I dysfunction mitochondrial disease, an area of critical unmet medical need. The